NCT01624766View on ClinicalTrials.gov

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 19, 2012

Primary Completion Date

February 24, 2021

Study Completion Date

February 24, 2021

Conditions
Advanced Malignant NeoplasmMetastatic Malignant NeoplasmRecurrent Malignant NeoplasmRefractory Malignant Neoplasm
Interventions
BIOLOGICAL

Anakinra

Given SC

BIOLOGICAL

Denosumab

Given SC

DRUG

Everolimus

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01624766 - Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers | Biotech Hunter | Biotech Hunter